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Introduction
Inflammation is a  biological reaction to disrupted 
tissue homeostasis, triggered by any interfering factor 
[1-4]. The World Health Organization (WHO) considers 
chronic inflammatory diseases as the greatest bur-
den to human health, affecting any organ of the body 
and among the major causes of death worldwide [3, 
5]. However, its role in the pathogenesis of the repro-
ductive system disorders is still debated [3]. Given the 
alarming epidemiology of chronic inflammation and the 
availability of suggestive data, non-microbial inflamma-
tion deserves further investigations to clarify whether 
it plays a  key role (at least in part) for obstetric and 
gynecological disease.
This work aims to review the concept of impaired 
inflammatory state of the endometrium (IISE) as a mul-
tifaceted approach to the problem of endometrial in-
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Abstract
New insights into the complex and fine-regulated inflammatory mechanisms involved in the endometrium 
reveal multiple facets to the problem of endometrial inflammation. However, the entity termed chronic endo-
metritis is to date restricted to infectious etiology and managed with antibiotics. Conversely, the concept of 
impaired inflammatory state of the endometrium (IISE) provides a more global approach to defective endome-
trial inflammation, considering both infectious and non-infectious etiology. A non-systematic review was done 
through a search on MEDLINE, EMBASE, Global Health, The Cochrane Library, Health Technology Assessment 
Database and Web of Science, research registers. Pertinent original and review articles, published in English 
or French until December 31, 2019, were selected. A  compelling body of evidence demonstrates transient, 
repeated and persistent IISE to be a major factor of most problematic disorders in obstetrics/gynecology, such 
as endometrial polyps, unexplained infertility, miscarriage, placenta-related pathology and endometrial cancer. 
When scheduled accordingly, hysteroscopy can play a key role in the IISE assessment. Robust data suggests the 
pertinence of minimal-effective anti-inflammatory regimens for therapeutic IISE targeting. 
This review provides a comprehensive update on the multiple facets of inflammation in the endometrial 
physiology and pathology. Further research is needed to improve classification, diagnosis and treatment of IISE.
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flammation, in contrast to the entity termed chronic 
endometritis (CE), currently restricted to infectious eti-
ology and managed with antibiotics. It gives insights 
into the endometrial inflammation as a  fundamental 
process, related to infectious and non-infectious fac-
tors, and involved both in physiologic and pathogenic 
conditions in obstetrics and gynecology, such as infertil-
ity, endometrial polyps, miscarriage and abnormal pla-
centation-related diseases.
Methods
A non-systematic review was done through a search 
on the following databases: MEDLINE, EMBASE, Global 
Health, The Cochrane Library (Cochrane Database of 
Systematic Reviews, Cochrane Central Register of Con-
trolled Trials, Cochrane Methodology Register), Health 
Corresponding author:
Antonio Simone Laganà, Department of Obstetrics and Gynecology, “Filippo Del Ponte” Hospital, 
University of Insubria, Piazza Biroldi 1, 21100, Varese, Italy, e-mail: antoniosimone.lagana@uninsubria.it 
Submitted: 30.03.2020
Accepted: 14.04.2020
Menopause Review/Przegląd Menopauzalny 19(2) 2020
91
Technology Assessment Database and Web of Science, 
research registers (such as www.cliniclatrials.gov); we 
used the medical subject heading (MeSH) term Inflam-
mation (MeSH Unique ID: D007249) in combination 
with: Endometrium (MeSH Unique ID: D004717); Endo-
metritis (MeSH Unique ID: D004716). We selected per-
tinent original and review articles, published in English 
or French until 31 December 2019, focusing about CE, 
endometriosis, endometrial polyps, infertility and pla-
centa-related complications, endometrial inflammation 
assessment and pharmacological targeting.
General features of the inflammatory response
Microbial pathogens, but also mechanical trauma, 
extreme temperatures, ischemia, hypoxia, foreign bod-
ies, pollutants, toxic, irritant, metabolic and allergenic 
agents are potent activators of the inflammatory re-
sponse [1-11]. Pathogen-associated molecular patterns 
(PAMPS) and/or damage-associated molecular patterns 
(DAMPS) are derived either from pathogens or dam-
aged cells and subsequently recognized by the pat-
tern-recognition-receptors of the host’s cells [7-9, 12, 
13]. The innate immune system, involving a variety of 
soluble molecules (cytokines) and immune cells, is first 
triggered, leading to a cascade of vascular and immune 
reactions. Subsequently, 4 to 7 days later, the adaptive 
immune system is eventually involved and consists of 
a  T or B-cells-mediated specific response against the 
antigen [10, 14-17]. The return to homeostasis is or-
chestrated by active pro-resolution pathways, limiting 
damage to the cells by clearing leukocytes and tissue 
debris, thus allowing prompt restoration of tissue and 
vascular functions [18-22] (Fig. 1).
Acute inflammation lasts less than 2 weeks and 
is characterized by 5 cardinal clinical signs: redness 
(rubor), heat (calor), edema (tumor), pain (dolor) and 
loss of function (functio laesa) [17]. Ideally, this results 
in a  restitutio ad intergrum of the tissue. However, 
inflammation could evolve, after a  subacute 2-to-6-
week phase, to chronicity, displaying different symp-
toms, as the acute inflammation cardinal signs be-
come mild or absent. These include constant fatigue, 
sleep disorders, depression, mood disorders, gastroin-
testinal complaints, weight gain, frequent infections, 
allergies and body pain [5, 23, 24]. Chronic inflamma-
tion is characterized by different cellular, vascular and 
histological features [5, 23, 24]. Furthermore, various 
causes and different mechanisms explain its patho-
genesis [3, 5, 17, 20, 25-28] (Fig. 2). The challenging 
Fig. 1. Schematic illustration of acute inflammation orchestrated by the innate and adaptive immune system
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deeper understanding of the inflammatory response 
in its molecular, humoral, cellular and histopathologi-
cal aspects should contribute to improved diagnostic 
and therapeutic strategies of inflammation-mediated 
pathologies.
The physiological inflammatory state  
of normal endometrium
A vast amount of literature acknowledges inflamma-
tion as a  key mechanism in physiological reproductive 
events, such as menstruation, ovulation, implantation 
Metabolic disorders (atherosclerosis, diabetes, dyslipidemia, obesity, etc.), hypertension, ischemia, hypoxia, oxidative 
stress, allergenic agents, pollutants, foreign particles, microbial pathogens, etc. 
Long-term exposure to a causative 
factor
Mononuclear cell infiltration
Failure in eliminating the acute 
inflammation causing agent 
Acute inflammation cardinal signs: 
absent or mild 
Abnormal immune response against 
a normal component of the body 
(autoimmune phenomena) 
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Fig. 2. Causes, mechanisms and features of chronic inflammation
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and gestation [3, 17, 23, 29-35]. Endometrial physiolo-
gy underlies a cyclical injury-healing process, displaying 
all the hallmarks of a self-limiting inflammation [17, 30]. 
Leukocytes are scattered in the stroma with aggrega-
tions around the glands [36] in a menstrual cycle-depen-
dent fashion: their proportion among stromal cells rang-
es from 8% in proliferative endometrium to 32% in early 
pregnancy decidua [31]. Neutrophils are the prominent 
leukocytes during menstruation and start increasing af-
ter progesterone withdrawal in late secretory phase [37]. 
Macrophages, eosinophils and activated mast cells have 
a similar distribution, yet in smaller proportions [17, 30, 
37]. The other main leukocytes of normal endometrium 
are CD56+ uterine natural killer (uNK) cells which account 
for 2% of stromal cells in proliferative endometrium, 17% 
during late secretory phase and more than 70% of en-
dometrial leukocytes at the end of the first trimester of 
pregnancy where they play a role in trophoblast invasion 
and increased spiral artery blood flow [31, 33-36, 38, 39]. 
They are however characterized by gradual decrease of 
their cytotoxic activity until suppression in late secretory 
phase and early stage of pregnancy, thus allowing a fa-
vorable environment for implantation [33, 40]. 
Studies have revealed fluctuating time-dependent 
quantitative and qualitative changes of the recruited leu-
kocytes (Fig. 3), the involved cytokines and the vascular 
aspects throughout the menstrual cycle and pregnancy 
[17, 23, 30-32, 34, 36-40]. The vascular changes main-
ly consist of vasoconstriction, vasodilatation, increased 
capillary permeability and angiogenesis. Interleukin (IL)-
1, IL-6, IL-8 and peptide growth factors are demonstrated 
to have a key role in reproductive physiology and pathol-
ogy, mainly via the prostaglandin biosynthetic pathway 
[17, 39, 41, 42]. Furthermore, studies have demonstrated 
the key role of active pro-resolution pathways aimed to 
control inflammation, thus allowing resumption of nor-
mal reproductive functions [17, 19-21]. Exacerbated ac-
tivation of pro-inflammatory pathways and/or failure of 
pro-resolution pathways have already been described as 
a cause of reproductive disorders [17, 40].
The impact of estradiol and progesterone on inflam-
mation has also been demonstrated as their receptors 
are expressed in all the cells of the innate and the adap-
tive immune systems [5, 43-46]. They can suppress the 
production and secretion of several pro-inflammatory 
markers, such as IL-6 and IL-1β [45, 46]. Furthermore, 
progesterone decreases the cytotoxic activity of uNK-
cells during secretory phase and pregnancy; and when 
decreased, it causes activation of some pro-inflamma-
tory mediators and neutrophils recruitment in the en-
dometrium [17, 33, 37, 47].
The concept of impaired inflammatory  
state of the endometrium 
The delicate balance of pro-inflammatory and 
pro-resolution mechanisms in normal endometrium is 
well documented, thus explaining how over-activation 
of inflammation is as problematic as its suppression 
[17, 45]. An objective assessment of “normal endo-
metrial inflammatory state” requires considering the 
time-changing quantitative and qualitative inflamma-
tory patterns of the endometrium. However, to date 
this evaluation is totally operator-dependent with 
a  consistent inter-observer variability. The diagnosis 
should rely on objective scores though, considering the 
stromal edema, the vascular patterns as well as the dis-
tribution and counts of the endometrial inflammatory 
markers for each reproductive phase. The observation 
of a “late-secretory-phase-pattern” during proliferative 
phase, for instance, may indicate an “impaired inflam-
matory state of the endometrium” (IISE).
IISE is a more appropriate terminology than “endo-
metritis”, especially because the latter literally means 
“inflammation of the endometrium”, regardless of its 
causative factor. Yet, inflammation is already a consis-
tent part of normal endometrium, the term “impaired” 
is thus more convenient for anomaly. 
Depending on the nature of the causative factor 
and the attenuating circumstances, the IISE is transient, 
repeated or persistent. A  transient IISE is an “out-of-
phase” inflammatory disorder caused by any interfer-
ing factor. In fact, the monthly chance of pregnancy in 
the average young and healthy fertile human couple is 
around 30% [48]. A transient IISE partially explains this 
low percentage. If persistent or recurrent, an IISE can 
have considerable consequences on fertility. It is well 
established today that repeated acute inflammation is 
one of the forms of chronic inflammation [5].
However, to date, most acknowledged forms of im-
paired endometrial inflammation only consider germs 
or foreign bodies as causative factors. “Acute endome-
tritis”, for instance, is defined as an acute response to 
pathogens. It is characterized by excessive exudation 
and leukocyte infiltration, predominantly granulocytes 
[23]. Specific endometritis is characterized by specific 
granulomatous lesions, such as the foreign body gran-
uloma and the tuberculosis granuloma [5]. Immunolog-
ical changes are also described in category E of abnor-
mal uterine bleeding of the International Federation 
of Gynecology and Obstetrics (FIGO AUB-E), previously 
denominated dysfunctional uterine bleeding. Among 
these changes: impaired prostaglandin activity [41, 
42, 46, 47], in addition to increased CD56+ cells during 
proliferative and early secretory phases (5% of stromal 
cells instead of 2%) [38]. 
“Persistent or recurrent IISE” is a  more accurate 
terminology than CE. To date, CE is an anatomo-clinical 
entity displaying a number of paradoxical features. In 
fact, histological diagnosis of CE is mainly based on the 
presence of plasma cells, normally absent or very low in 
the endometrium [23, 49-54]. Therefore, this definition 
does not take into consideration the other impaired in-
flammatory parameters of the endometrium. 
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In addition, hysteroscopic diagnosis of CE is con-
sensually based on the presence of strawberry pattern, 
focal hyperemia, hemorrhagic spots, micro-polyps and 
stromal edema [51, 53, 55, 56] (Fig. 4). However, it is 
well established in immunology that hyperemia and 
edema are typical cardinal signs for acute inflamma-
tion, not the chronic one which is rather silent [5, 24]. 
The presence of acute inflammation signs can be ex-
plained though by the fact that chronic inflammation 
makes perfect ground for repeated acute episodes. CE 
has already been histologically demonstrated in pa-
tients free of hysteroscopic signs, since negative pre-
dictive values range from 83 to 89%, i.e. in about 10 to 
20% of patients with normal hysteroscopy, there was 
histological evidence of CE [55-57]. Limited observer 
agreement is a  possible explanation. Nonetheless, re-
cent literature concludes that absence of hysteroscopic 
features does not rule out CE [57]. Conversely, positive 
predictive values range from 42 to 94%, which is low 
in most studies [57]. This indicates either a  transient 
IISE, or limited histological diagnostic tools due to the 
absence of a rigorous definition of endometrial inflam-
matory patterns.
Furthermore, germs and/or altered microbiota are, 
to date, the unique cause admitted for chronic inflam-
mation in human endometrium, and exclusively man-
aged with antibiotics [35, 49, 53-56, 58-60]. Despite 
absence of evidence of pathogens in 25% of women 
diagnosed for CE [56], and despite hysteroscopic per-
sistence of CE after antibiogram-based antibiotic thera-
py in 28% of patients [59], only germs are targeted, and 
never inflammation as an independent process, nor the 
other possible causes of impaired inflammation. 
Migration of circulating B lym phocytes to the en-
dometrial stromal compartment has been found to 
be induced by gram-negative bacteria [54]. However, 
the growing concept of microbiota has demonstrated 
a potential co-existence between microorganisms and 
healthy endometrium without causing disease [50, 60]. 
Underlying conditions predisposing to impaired endo-
metrial inflammation are susceptible of altering the 
microenvironment, leading to impaired microbiota or 
pathogens, thus causing a vicious circle. For that mat-
ter, recently published results of a trans-sectional pre-
liminary analysis of an ongoing case-control study [61], 
evaluated with DNA sequencing the endometrial and 
vaginal microbiota during the implantation window in 
patients suffering from repeated implantation failure 
(RIF) versus control group. Despite limited number of 
enrolled patients (28 in RIF and 18 in control group), one 
of the main findings was that endometrial microbiota, 
and not the vaginal one, showed a marked variance be-
Fig. 4. Hysteroscopic signs of what is termed chronic endometritis. A) micropolyps; B) hyperemia: red spots and petechiae; 
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tween the individuals. One confounding factor claimed 
to explain it was the different types of cycles (natural, 
hCG-triggered and hormone replacement cycles).
Regarding non-infectious inflammatory etiology, 
a higher prevalence of CE was correlated with endome-
triosis, a history of prolonged menstrual bleeding epi-
sodes, infertility, abortion and fallopian tube obstruc-
tion [52, 62]. Furthermore, there is evidence regarding 
the impact of non-infectious conditions on the endo-
metrial fine-regulated inflammatory balance. In fact, 
multiple impaired inflammatory mechanisms of the 
endometrium have been demonstrated in heavy men-
strual bleeding, abnormal implantation/placentation–
related issues, such as infertility, recurrent miscarriage, 
congenital anomalies, stillbirth, preterm delivery, fetal 
growth restriction and pregnancy-induced hyperten-
sion. They consist of increased uNK-cells during prolif-
erative and early secretory phases; higher percentage of 
uNK-cells expressing activation-antigens; elevated lev-
els of T helper (Th) 1 cells contrasting with low Th2-cells 
and over-activation of the prostaglandin inflammatory 
pathway [33-35, 38-40, 45, 63-67]. There is clear evi-
dence that controlled immune functions play a pivotal 
role in initiating a normal pregnancy, as they modulate 
the decidual response, cytokine balance, vascular adap-
tation, epithelial embryo attachment, trophoblast inva-
sion, placental morphogenesis and also immune toler-
ance [45]. It is well documented that any disequilibrium 
in favor of suppressed or excessive inflammation in the 
endometrium significantly affects fertility or placental 
morphogenesis, subsequently leading to the above-cit-
ed gestational disorders [45, 67]. 
In addition, analysis of the acknowledged risk fac-
tors for preeclampsia by the U.S. Preventive Services 
Task Force guideline [68] shows that most of them are 
risk factors for chronic inflammation too: age of 35 
years or older, body mass index greater than 30, chron-
ic hypertension, type 1 or 2 diabetes, renal disease and 
autoimmune disease (such as systemic lupus erythe-
matosus and antiphospholipid syndrome). 
Metabolic disorders, such as diabetes, dyslipidemia, 
hypertension and obesity, have been ascertained to 
over activate the immune system, causing leukocyte 
activation, with greater numbers of leukocytes with 
pro-inflammatory phenotypes, thus explaining predis-
position to chronic inflammatory diseases [25, 27]. They 
are well established risk factors for endometrial cancer 
too, which is already acknowledged as a chronic inflam-
mation-mediated condition [17, 69, 70]. They are also 
significantly associated with increased risk of abnormal 
uterine bleeding, fertility issues as well as miscarriage 
and stillbirth, with remarkable improvement obtained 
with stricter metabolic control [71-73]. 
The oxidative stress, mediated by toxic habits (such 
as smoking), excessive pollution, allergies, sleep disor-
ders and increasing age, is also demonstrated to pre-
dispose to chronic inflammatory state. Correlation with 
unexplained infertility, spontaneous abortion, recurrent 
pregnancy loss and preeclampsia has been document-
ed [5, 74-77]. 
Additionally, the physiological effect of sex hor-
mones on endometrial inflammation may explain both 
transient and persistent IISE in case of hormonal im-
balances [17, 40-44, 78]. The borderline between “hor-
mone-dependent” and “inflammation-mediated” dis-
order thus becomes blurred, as hormone imbalances 
induce impaired inflammation. Conversely, the latter 
alters hormone receptors’ expression both in epithelial 
and stromal cells, thus maintaining a vicious circle [54]. 
Stress was also demonstrated to induce localized 
inflammation in the uterus and cause an immune–en-
docrine disequilibrium involved in infertility, miscar-
riage, late pregnancy complications and impaired fetal 
development, mainly via elevated levels of cortisol as 
well as significant reduction in progesterone levels fol-
lowed by impaired activity of uNK-cells [35, 78, 79]. 
In endometriosis, altered expression of estrogen 
and progesterone receptors has been associated with 
resistance to progesterone and over-expression of 
pro-inflammatory cytokines, such as IL-1, IL-6 and tu-
mor necrosis factor α (TNF-α). Auto-antibodies against 
endometrial cells have also been described in endo-
metriosis [32, 35, 63, 80-82]. Recent data found in pa-
tients with endometriosis a different behavior of some 
endometrial immune cells (macrophages, dendritic cells 
and T cells). The latter display more pro-inflammatory 
properties, compared to women without the disease 
[83, 84].
In adenomyotic nodules, high levels of inflamma-
tory and neurogenic mediators have been reported 
[85]. The latter is demonstrated to be correlated with 
a higher incidence of implantation failure and abnormal 
placentation-related complications like miscarriage and 
pregnancy-induced hypertension [64, 86-88].
Auto-immune, allergenic and chronic inflammatory 
diseases directly interfere with the immune system and 
are correlated with decreased fertility [11, 25, 28, 35]. 
Even in the absence of a  clinically overt autoimmune 
disease, anti-phospholipid, anti-thyroid, or antinuclear 
autoantibodies have been reported to be correlated 
with implantation failure and early pregnancy loss, es-
pecially when associated to vasculitis [65].
Semen-induced inflammation is another possible 
cause for IISE that has never been properly assessed 
in human reproductive medicine. In several animal spe-
cies however, a  transient post-mating uterine inflam-
mation, triggered by semen components, is considered 
physiological [89-91]. It becomes pathological in case 
of inflammatory disequilibrium in favor of pro-inflam-
mation, which is demonstrated to cause persistent en-
dometritis, correlated with decreased fertility, requiring 
treatment like immuno-stimulants and corticosteroids 
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[92]. In humans, the only acknowledged form of se-
men-induced inflammation is semen allergy, a rare and 
most likely underrated condition, poorly known by prac-
titioners and thus, poorly investigated [93-96].
Furthermore, endometrial polyp (EP) is an anato-
mo-clinical entity that appears strongly related to IISE. 
It is a benign hyperplastic overgrowth of endometrial 
glands and stroma affecting 7.8% to 50% of women, 
with a  prevalence of malignancy ranging from 1 to 
3%, particularly in post-menopausal patients [97-103]. 
Spontaneous regression has been reported in 6.3 to 
25% of cases [97, 104]. Although its etiopathogenesis is 
still unknown, it is usually presented as a hormone-re-
lated condition [103, 105, 106]. Yet, there is to date 
sufficient evidence indicating an inflammation-medi-
ated pathogenesis, especially as hormonal imbalances 
are demonstrated to interfere with the inflammatory 
state of the endometrium [65, 99, 106]. Risk factors for 
EP are those for chronic inflammation: increasing age, 
menopause, obesity and hypertension [99, 102]. High-
er prevalence of EP has been reported in women with 
diabetes mellitus [107-109], adenomyosis [110], endo-
metriosis [111] and CE [112, 113]. In addition, studies 
have demonstrated increased expression of transform-
ing growth factor α1 (TGF-α1) and vascular endothelial 
growth factor (VEGF) in EP [101, 113, 114]. Both are 
important pro-inflammatory mediators identified in 
many chronic inflammatory diseases [115-120]. The 
prevalence of EP in patients with IUD does not seem to 
have been assessed. Meanwhile, studies have report-
ed cases for ParaGard copper and levonorgestrel IUD 
[121], despite therapeutic properties of this latter on 
endometrial hyperplasia [122]. The causal relationship 
between EP and infertility has been confirmed in only 
one randomized trial [102]. The acknowledged expla-
nation is that EPs cause endometrial inflammation and 
sometimes constitute a  mechanical barrier to sperm 
transportation or embryo implantation [102, 103, 105]. 
Current evidence rather indicates EP as an inflamma-
tion-mediated neo-process, subsequently maintaining 
the inflammatory state. This vicious circle partially ex-
plains why resection of EP is associated with increased 
rates of pregnancy in infertile women [100, 102].
Very importantly, gynecological malignancies, 
mainly cervical and endometrial ones, have also been 
demonstrated to be related to chronic inflammation, be 
it mediated by infectious or non-infectious conditions 
[17, 69, 70, 123]. This highlights the long-term impor-
tance of proper diagnosis and management of chronic 
inflammation.
IISE assessment and management: future 
perspectives
To date, there are no guidelines allowing proper 
assessment or management of endometrial inflam-
mation. Elaborating clinical scores to assess the global 
inflammatory risk for patients appears pertinent. The 
patient’s clinical assessment should consider: her age, 
lifestyle, body mass index, blood pressure, atopy, stress 
factor, chronic inflammation signs, as well as a medi-
cal history of inflammation-mediated diseases and 
abnormal placentation-related disorders. Hysteroscopy 
should be scheduled during proliferative phase, as in-
flammation-hallmarks are the poorest at this stage. 
Acute inflammation signs suggest either a transient 
or a  persistent IISE. Absence of signs should not ex-
clude persistent IISE as it is normally macroscopically 
silent. If semen-allergy is suspected, introducing the 
concept of “post coital hysteroscopy” appears relevant 
and remains to define in order to assess post-coital in-
flammation both macroscopically (redness, edema) and 
microscopically (assessment of mast-cells and eosino-
phils’ distribution). More attention has to be given to 
micro-hysteroscopy as it already defines vascular pat-
terns for the endometrium [124]. Further research is 
highly needed, also for histopathology that should be 
revised and based on normal and impaired inflammato-
ry patterns, and performed by trained pathologists. De-
spite its cost, the superiority of immunohistochemistry 
is indisputable as it allows a better identification of the 
positively stained cells for all antigens [52].
The optimal inflammatory balance allowing a prop-
er implantation and progression of a healthy pregnancy 
seems quite delicate. In fact, spontaneous resolution of 
reproductive issues may occur without any medication. 
This highlights the importance of a  healthy lifestyle, 
such as weight loss, controlling metabolic diseases, ex-
ercise and/or reduced stress. 
Etiologic context must be targeted whenever pos-
sible. Anti-inflammatory therapy has to be considered 
as well. There is increasing evidence about its effective-
ness in animal models for instance [19, 92]. In humans, 
several authors stress the necessity of introducing ef-
fective therapies capable of modulating the immune 
endometrial reproductive functions [30, 45, 80-82, 85]. 
In order to restore the normal endometrial inflamma-
tory balance, minimal effective doses of pro-resolving 
anti-inflammatory drugs appear more relevant. 
Although anti-inflammatory therapy has poorly 
been considered in the management of impaired en-
dometrial inflammation, there is suggestive data high-
lighting the benefits of some molecules, such as low-
dose acetylsalicylic acid (ASA). Its mechanism of action 
in the prevention of preeclampsia has never been eluci-
dated [125] although there is evidence demonstrating 
its pro-resolving anti-inflammatory effect [22, 126]. De-
pending on the modalities of prescription, encouraging 
outcomes were reported regarding perinatal death, pre-
eclampsia, fetal growth, preterm birth and fecundability 
[125, 127-129]. Furthermore, it is very often well-toler-
ated by women, fetuses and neonates [130]. 
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Corticosteroids’ pro-resolving anti-inflammatory 
properties are widely demonstrated as well [67, 131-
133]. Positive live birth outcomes in unexplained infer-
tility and idiopathic recurrent miscarriage were obtained 
with low (or medium) dose of dexamethasone, prednis-
olone or prednisone, yet with low evidence level [67, 
132, 134, 135]. Nevertheless, many adverse maternal 
and fetal effects were reported in the studies where cor-
ticosteroids were administered at high doses [45, 136]. 
Moreover, other molecules need to be assessed such as 
non-steroid-anti-inflammatory drugs (NSAIDs), whose 
prolonged prescription could oppose to follicle rupture 
though [137]. Prostaglandin E2 inhibitors have already 
been suggested to decrease the inflammatory environ-
ment caused by endometriosis and thus enhance en-
dometrial receptivity for improved implantation [138]; 
metformin and dehydroepiandrosterone (DHEA), have 
been found to have anti-inflammatory properties [135, 
139, 140]. Finally low-dose heparin, used in antiphos-
pholipid autoimmune syndrome, has shown safe and 
effective anti-inflammatory properties in addition to its 
anticoagulant effect [141, 142]. 
Conclusions
Endometrial inflammation is a complex key-part of 
the endometrial physiology, regulated by a  fine-regu-
lated balance between pro-inflammatory and pro-re-
solving mechanisms, and involved in all reproductive 
events. 
Infectious agents should no longer be considered 
as the only disturbing agent causing IISE. Any condi-
tion interfering with the immune system could result in 
a transient, repeated or persistent IISE. The latter could 
display very poor clinical and paraclinical signs. Optimal 
diagnostic and therapeutic tools remain to determine, 
yet, minimal effective doses of inflammation-pro-re-
solving therapies appear promising. Further research 
is needed for a better assessment of the inflammatory 
pathways involved in the reproductive tract, as well as 
the hysteroscopic and pathological patterns of normal 
and impaired endometrium, in order to improve pre-
vention, diagnosis and treatment of obstetric and gy-
necological disorders.
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